Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
In an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in ...
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 10 unusual trades. Delving into the ...
Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell ...
That latest invention — an electromagnetic system capable of separating oil from water — scored her another award at the Regeneron ISEF this year. “Crude oil spills destroy shorelines, imbalance ...
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has announced positive Phase II results for two novel monoclonal antibodies targeting distinct domains of Factor XI, supporting its bid to bring new ...
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results … ...
Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year. The company said REGN7508 is ...
Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control ...
A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback